Vertex's Inaxaplin Hits Phase 2b Marks in Broader APOL1 Kidney Disease Populations
- Vertex's oral APOL1 inhibitor inaxaplin met Phase 2b AMPLIFIED goals in two new AMKD populations beyond the original cohort.
- Among 41 patients, Week 13 UACR fell 42.7% with modest proteinuria (n=23) and 17.3% with AMKD plus type 2 diabetes (n=18).
- This broadens inaxaplin's market as pivotal AMPLITUDE trial enrollment completes, with interim data due early 2027.
💡 Points
APOL1-mediated kidney disease has essentially no targeted competition — a genetically defined, high-unmet-need population overwhelmingly of African ancestry that mainstream nephrology has largely ignored — and Vertex is quietly building the second pillar of its post-CF story there. Widening efficacy into milder-proteinuria and diabetic AMKD subgroups ahead of AMPLITUDE's 2027 readout meaningfully expands the addressable market and de-risks the label.
Vertex's midstage data amplify kidney disease market opportunity ↗